NEW YORK, Sept. 13, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Acacia Communications, Inc. (NASDAQ:ACIA) from August 11, 2016 through July 13, 2017, inclusive (the “Class Period”) of the important October 13, 2017 lead plaintiff deadline in the class action.. The lawsuit seeks to recover damages for Acacia investors under the federal securities laws.
To join the Acacia class action, go to http://rosenlegal.com/cases-1164.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Acacia’s manufacturing and quality control processes were deficient; (2) the foregoing deficiencies were likely to disrupt Acacia’s manufacturing, thereby impacting Acacia’s revenues; and (3) as a result of the foregoing, Acacia’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1164.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Italy Fines Apple €98.6 Million Over App Store Dominance
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



